In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

European stocks closed higher on Thursday amid optimism the Chinese government will announce more stimulus measures to help spur ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...

Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on ...

Evotec has joined forces with Novo Nordisk to advance the clinical and commercial manufacturing of stem cell-based therapies.

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This summary covers key developments in the pharmaceutical sector, including Pfizer's initiatives in low-income nations, challenges faced by Canadian provinces in drug treatment policies, major trial ...

A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.

The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Tagrisso (osimertinib), which is ...

Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo ...

EU mid-market update: Ceasefire on the cards for Israel/Lebanon; China reiterates forceful rate cuts; Focus on Powell, weekly ...